Filing Flows › PTC Therapeutics (PTCT) › Q3 2026 › vs Q3 2025
PTC Therapeutics (PTCT) Q3 2026 vs Q3 2025 (year over year)
PTC Therapeutics's revenue rose $147M (+70%) from $211M in Q3 2025 to $358M in Q3 2026. The biggest changes: Net product revenue +$145M (+111%); Royalty revenue +$10.9M (+15%); Collaboration and license revenue −$9.0M (-98%).
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Sephience | $182M | $19.6M | $162M | +830% |
| Translarna | $48.5M | $50.7M | −$2.2M | -4% |
| Emflaza | $25.1M | $35.2M | −$10.1M | -29% |
| Upstaza/Kebilidi | $14.6M | $15.7M | −$1.2M | -8% |
| All other products | $5.9M | $9.8M | −$4.0M | -40% |
| Net product revenue | $276M | $131M | $145M | +111% |
| Royalty revenue | $81.7M | $70.8M | $10.9M | +15% |
| Collaboration and license revenue | $229K | $9.3M | −$9.0M | -98% |
| Revenue | $358M | $211M | $147M | +70% |
| Net loss | $51.7M | −$15.9M | $67.6M | — |
| Costs & expenses | $410M | $250M | $160M | +64% |
| Operating costs | $333M | $208M | $125M | +60% |
| Interest & other, net | $66.2M | $26.1M | $40.1M | +154% |
| Income tax | $10.6M | −$39.0M | $49.6M | — |
| Research & development | $105M | $100M | $5.2M | +5% |
| SG&A | $80.1M | $84.0M | −$4.0M | -5% |
| Other operating costs | $147M | $23.8M | $123M | +519% |
| Operating cash sources | $66.0M | $96.8M | −$30.9M | -32% |
| Depreciation & amortization | $16.8M | $11.1M | $5.7M | +51% |
| Share-based compensation | $23.8M | $19.4M | $4.4M | +23% |
| Cash used in operations | $25.3M | $66.3M | −$41.0M | -62% |
| Net loss absorbed | $51.7M | −$15.9M | $67.6M | — |
| Working capital & other | $14.3M | $113M | −$98.5M | -87% |
Questions
How much did PTC Therapeutics's revenue grow year over year in Q3 2026?
PTC Therapeutics's revenue rose $147M (+70%) from $211M in Q3 2025 to $358M in Q3 2026.
What drove PTC Therapeutics's revenue change in Q3 2026?
Net product revenue +$145M (+111%); Royalty revenue +$10.9M (+15%); Collaboration and license revenue −$9.0M (-98%).